



**RSM-2 Medical Use Preceptor Statement**  
**Documentation of Supervised Clinical Case Experience**

Name of Proposed Authorized User: \_\_\_\_\_

**3701:1-58-32 – Use of unsealed radioactive material for uptake, dilution and excretion studies for which a written directive is not required**

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-32	C-14 Urea Capsules	H. Pylori infection: 0.001 mCi	Oral	
3701:1-58-32	I-123 Sodium Iodide	Thyroid uptake: 0.100 - 0.200mCi	Oral	
3701:1-58-32 (Other )				
3701:1-58-32 (Other )				

**3701:1-58-34 – Use of unsealed radioactive material for imaging and localization studies for which a written directive is not required**

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-34	F-18 FDG (Fluorodeoxyglucose)	Fludeoxyglucose F-18 Injection for positron emission tomography (PET) imaging: 5-15 mCi	Intravenous	
3701:1-58-34	F-18 Florbetapir (Amyvid)	Positron Emission Tomography (PET) imaging of Alzheimer's Disease (AD) and other causes of cognitive decline: 10 mCi	Intravenous	
3701:1-58-34	F-18 Flurpiridaz	Cardiac Imaging	Intravenous	
3701:1-58-34	Ga-67 (Gallium Citrate)	Abscess or Tumor imaging: 10 mCi	Intravenous	
3701:1-58-34	Ga-67 (Gallium Citrate)	Ga-67/MDP dual bone imaging: 5 mCi	Intravenous	
3701:1-58-34	Ga-67 (Gallium Citrate)	Heart Scan: 6 mCi	Intravenous	
3701:1-58-34	Ga-67 (Gallium Citrate)	Sarcoidosis evaluation: 5 mCi	Intravenous	

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-34	I-123 Ioflupane (DaTScan)	Parkinsonian evaluation(brain imaging): 5 mCi	Intravenous	
3701:1-58-34	I-123 Sodium Iodide	Thyroid uptake and scan: 0.200mCi	Oral	
3701:1-58-34	I-123 Sodium Iodide	Total body scan: 2.5 mCi	Oral	
3701:1-58-34	In -111 Pentetreotide (Octreoscan)	Localization of neuroendocrine tumors: 6 mCi	Intravenous	
3701:1-58-34	In 111 Capromab Pendetide (Prostascint)	Imaging biopsy-proven prostate cancer: 6 mCi	Intravenous	
3701:1-58-34	In-111 Oxyquinolone (In-111 Oxine)	Detection of inflammatory processes: 0.5 mCi	Intravenous	
3701:1-58-34	In-111 Pentetate (In-111 DTPA)	Cisternography: 0.500 mCi	Intrathecal	
3701:1-58-34	Iobenguane I-123 (ADREVIEW)	Heart Failure: 10 mCi	Intravenous	
3701:1-58-34	Iobenguane I-123 (ADREVIEW)	Detection of primary or metastatic pheochromocytoma or neuroblastoma: 10 mCi	Intravenous	
3701:1-58-34	Rb-82 Chloride	Cardiac Imaging	Intravenous	
3701:1-58-34	Tc 99m Filtered Sulfur Colloid	Bone marrow imaging: 10 mCi	Intravenous	
3701:1-58-34	Tc 99m Filtered Sulfur Colloid	Lymphedema: 2 mCi	Intradermal / Subcutaneous	
3701:1-58-34	Tc 99m Filtered Sulfur Colloid	Needle localization(LOC): 0.400 mCi	Intradermal / Subcutaneous	
3701:1-58-34	Tc 99m Filtered Sulfur Colloid	Melanoma(LYM): 0.400 mCi	Intradermal / Subcutaneous	
3701:1-58-34	Tc 99m Filtered Sulfur Colloid	Lymphoscintigraphy (LIJ): 0.400 mCi	Intradermal / Subcutaneous	
3701:1-58-34	Tc 99m Labeled Red Blood Cells (UltraTag RBC)	Rest MUGA Scan: 25 mCi	Intravenous	
3701:1-58-34	Tc 99m Labeled Red Blood Cells (UltraTag RBC)	Stress MUGA Scan: 30 mCi	Intravenous	
3701:1-58-34	Tc 99m Labeled Red Blood Cells (UltraTag RBC)	Gastrointestinal bleeding detection: 25 mCi	Intravenous	
3701:1-58-34	Tc 99m Mertiatide (MAG3)	Renal imaging: 10 mCi	Intravenous	
3701:1-58-34	Tc 99m Sulfur Colloid	Liver/Spleen imaging: 5 mCi	Intravenous	
3701:1-58-34	Tc 99m Sulfur Colloid	Gastric emptying: 0.5 mCi	Oral	

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-34	Tc 99m Sulfur Colloid	Gastric aspiration: 1 mCi	Oral	
3701:1-58-34	Tc-99m Albumin Aggregated (MAA)	Pulmonary perfusion study: 4 mCi	Intravenous	
3701:1-58-34	Tc-99m Albumin Aggregated (MAA)	Pregnancy pulmonary perfusion: 2.5 mCi	Intravenous	
3701:1-58-34	Tc-99m Albumin Aggregated (MAA)	Codmen pump: 3 mCi	Inject into Pump	
3701:1-58-34	Tc-99m Albumin Aggregated (MAA)	Hepatic artery perfusion: 4 mCi	Hepatic Arterial Catheter or Infusion Pump	
3701:1-58-34	Tc-99m Albumin Aggregated (MAA)	Right to left cardiac shunt: 3 mCi	Intravenous	
3701:1-58-34	Tc-99m Bicisate (Neurolite)	Ictal and Interictal Brain SPECT Imaging: 30 mCi	Intravenous	
3701:1-58-34	Tc99m Exametazime (Ceretec)	Detection of altered regional cerebral perfusion in stroke: 20 mCi	Intravenous	
3701:1-58-34	Tc-99m Mebrofenin (Choletec)	5 mCi	Intravenous	
3701:1-58-34	Tc-99m Mebrofenin (Choletec)	7 mCi (serum bilirubin level > 1.5 mg/dL)	Intravenous	
3701:1-58-34	Tc-99m Medronate (MDP)	25 mCi <220 lbs ≥ 30 mCi	Intravenous	
3701:1-58-34	Tc-99m Medronate (MDP)	with WBC study 20 mCi <220 lbs ≥ 25 mCi	Intravenous	
3701:1-58-34	Tc-99m Medronate (MDP)	Pediatric (0.3 mCi/kg)	Intravenous	
3701:1-58-34	Tc-99m Pentetate (DTPA)	Pulmonary ventilation 30 mCi	Aerosol	
3701:1-58-34	Tc-99m Pentetate (DTPA)	Pregnancy pulmonary ventilation: 20 mCi	Aerosol	
3701:1-58-34	Tc-99m Pentetate (DTPA)	GFR estimation 8 mCi	Intravenous	
3701:1-58-34	Tc-99m Pentetate (DTPA)	Brian imaging 25 mCi	Intravenous	
3701:1-58-34	Tc-99m Sestamibi (Cardiolite)	Rest Myocardial perfusion: 9 - 35 mCi	Intravenous	
3701:1-58-34	Tc-99m Sestamibi (Cardiolite)	Stress Myocardial perfusion: 30 - 45 mCi	Intravenous	
3701:1-58-34	Tc-99m Sodium Pertechnetate	Meckels study: 10 mCi	Intravenous	

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-34	Tc-99m Sodium Pertechnetate	Salivary gland imaging: 9 mCi	Intravenous	
3701:1-58-34	Tc-99m Sodium Pertechnetate	Testicular imaging: 20 mCi	Intravenous	
3701:1-58-34	Tc-99m Sodium Pertechnetate	Thyroid imaging: 5 mCi	Intravenous	
3701:1-58-34	Tc-99m Succimer (DMSA)	Evaluation of renal parenchymal : 5 mCi	Intravenous	
3701:1-58-34	Tc-99m Tilmanocept (Lymphoseek)	0.400 - 0.500 mCi	Intradermal / Subcutaneous	
3701:1-58-34	Tl-201 (Thallous Chloride)	Myocardial perfusion: 1-4 mCi	Intravenous	
3701:1-58-34 (Other)				
3701:1-58-34 (Other)				

- 3701:1-58-37 – Use of unsealed radioactive material for which a written directive is required
- 3701:1-58-37 – Oral administration of NaI I-131 requiring a written directive in quantities ≤ 33 millicuries
- 3701:1-58-37 – Oral administration of NaI I-131 requiring a written directive in quantities > 33 millicuries
- 3701:1-58-37 – Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required
- 3701:1-58-37 – Parenteral administration of any other radionuclide for which a written directive is required

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-37	I-131 Sodium Iodide	≤ 33 mCi - Treatment of Hyperthyroidism	Oral	
3701:1-58-37	I-131 Sodium Iodide	> 33 mCi - Treatment of Thyroid Carcinoma	Oral	
3701:1-58-37	I-131 Sodium Iodide	Total body scan: 2.5 mCi	Oral	
3701:1-58-37	Ra-223 dichloride (Xofigo)	Treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease: 1.35 µCi/kg	Intravenous	
3701:1-58-37	Sm-153 lexidronam (Quadramet)	Relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan: 1.0 mCi/kg	Intravenous	
3701:1-58-37	Sr-89 Strontium Chloride (METASTRON)	Relief of bone pain in patients with painful skeletal metastases: 4 mCi or 40-60 µCi/kg	Intravenous	
3701:1-58-37	Y-90 Ibritumomab Tiuxetan (Zevalin)	Non-Hodgkin's lymphoma treatment - 0.4 mCi/kg or 0.3 mCi/kg Y-90 Zevalin intravenous: Max dose 32 mCi	Intravenous	

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-37 (Other)				
3701:1-58-37 (Other)				
3701:1-58-37 (Other)				

**3701:1-58-43 - Use of manual brachytherapy sources**

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-43	Cs-137	Manual Brachytherapy - Interstitial	n/a	
3701:1-58-43	Cs-137	Manual Brachytherapy - Intracavitary	n/a	
3701:1-58-43	Cs-137	Manual Brachytherapy - Topical	n/a	
3701:1-58-43	I-125	Manual Brachytherapy - Eye Plaque	n/a	
3701:1-58-43	I-125	Manual Brachytherapy - Interstitial	n/a	
3701:1-58-43	Pd-103	Manual Brachytherapy - Interstitial	n/a	
3701:1-58-43 (Other)				
3701:1-58-43 (Other)				

**3701:1-58-55 – Use of teletherapy units**

**3701:1-58-55 – Use of remote afterloader units (HDR)**

**3701:1-58-55 – Use of gamma stereotactic radiosurgery units**

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-55	Co-60	Gamma Stereotactic Radiosurgery	n/a	
3701:1-58-55	Co-60	Teletherapy	n/a	
3701:1-58-55	Cs-137	Low Dose Rate Remote Afterloader	n/a	
3701:1-58-55	Ir-192	High Dose Rate Remote Afterloader	n/a	

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-55	Sr-90	Ophthalmic Application - Eye Lesions	n/a	
3701:1-58-55		Manual Brachytherapy - Intraluminal	n/a	
3701:1-58-55 (Other)				
3701:1-58-55 (Other)				

**3701:1-58-72 - Other medical uses of radioactive material or radiation from radioactive material**

OAC Modality	Radionuclide/Drug	Dose Amount	Route	Number of Supervised Clinical Cases
3701:1-58-72	Co-60	Gamma Stereotactic Radiosurgery - Gamma Knife Perfexion	n/a	
3701:1-58-72	I-125	Radioactive Seed Localizations for Localization of Non-Palpable Lesions	n/a	
3701:1-58-72	Y-90 SIR-Spheres	SIR-Spheres for the treatment of unresectable metastatic liver tumors from primary colorectal cancer.	Implantation via VIR	
3701:1-58-72	Y-90 TheraSpheres	TheraSpheres for the treatment of unresectable HCC	Implantation via VIR	
3701:1-58-72 (Other)				
3701:1-58-72 (Other)				

**THE SUPERVISED CLINICAL CASES INDICATED ABOVE WERE OBTAINED UNDER THE SUPERVISION OF**

Supervising Individual: \_\_\_\_\_ Signature: \_\_\_\_\_

Title of Supervising Individual: \_\_\_\_\_

License Number Listing Supervising Individual: \_\_\_\_\_

Institution Name and Location: \_\_\_\_\_

Preceptor Meets the Training and Experience Requirements of the Following Use(s):

- 3701:1-58-32   
 3701:1-58-34   
 3701:1-58-37   
 3701:1-58-43  
 3701:1-58-53   
 3701:1-58-55   
 3701:1-58-72 \_\_\_\_\_